Tan XL et al. – The data suggest that aspirin use, but not non-aspirin nonsteroidal anti-inflammatory drugs (NSAID) use, is associated with lowered risk of developing pancreatic cancer
- The authors used a clinic-based case-control study of 904 rapidly ascertained histologically or clinically documented pancreatic ductal adenocarcinoma cases, and 1,224 age- and sex-matched healthy controls evaluated at Mayo Clinic from April 2004 to September 2010.
- Overall, there is no relationship between non-aspirin NSAID or acetaminophen use and risk of pancreatic cancer.
- Aspirin use for 1d/mo or greater was associated with a significantly decreased risk of pancreatic cancer (OR=0.74, 95% CI: 0.60-0.91, P=0.005) compared with never or less than 1 d/mo.
- Analysis by frequency and frequency-dosage of use categories showed reduced risk (P=0.007 and 0.022, respectively).
- This inverse association was also found for those who took low-dose aspirin for heart disease prevention (OR=0.67, 95% CI: 0.49-0.92, P=0.013).
- In subgroup analyses, the association between aspirin use and pancreatic cancer was not significantly affected by pancreatic cancer stage, smoking status, or body mass index.